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Summary 
Glioblastoma multiforme (GBM) is an extremely heterogeneous 
disease despite its seemingly uniform pathology. Deconvolution of The 
Cancer Genome Atlas’s GBM gene expression data has unveiled the 
existence of distinct gene expression signatures underlying discrete 
GBM subgroups. Recent conflicting findings proposed that microRNA-
10b exclusively regulates glioma growth or invasion but not both. We 
showed that silencing of microRNA-10b by baculoviral decoy vectors in 
a glioma cell line resembling the mesenchymal subgroup of GBM 
reduces its growth, invasion and angiogenesis whilst promoting 
apoptosis in vitro. In an orthotopic human glioma mouse model, 
inhibition of microRNA-10b diminishes the invasiveness, angiogenicity 
and growth of mesenchymal glioma cells in the brain and significantly 
prolonged survival of glioma-bearing mice. We demonstrated that the 
pleiotropic nature of microRNA-10b was due to its suppression of 
multiple tumor suppressors including TP53, FOXO3, CYLD, PAX6, 
PTCH1 and NOTCH1. By interrogation of the REMBRANDT database, 
we noted that dysregulation of many direct targets of microRNA-10b 
was associated with significantly poorer patient survival. Thus, our 
studies uncovered a novel role for microRNA-10b in regulating 
angiogenesis and suggest that microRNA-10b may be a pleiotropic 
regulator of gliomagenesis. 
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Chapter 1. Introduction 
1.1 Discovery, biogenesis and mechanisms of action of 
microRNAs 
Initial discoveries of microRNAs (miRNA) were made by Ambros and 
colleagues who identified lin-4 in C. elegans as a short RNA transcript 
with partial sequence complementarity to regions in the 3’ untranslated 
region (UTR) of lin-14, thereby regulating LIN-14 protein synthesis (1). 
Down-regulation of LIN-14 signals the end of the first larval stage and 
progression into the second larval stage. Seven years later, the let-7 
miRNA was discovered (2). Akin to lin-4, let-7 has been shown to 
regulate developmental timing in C. elegans (2). This groundbreaking 
finding accelerated the identification of miRNAs as a class of single-
stranded RNAs of 18-25 nucleotides in length that is prevalent in the 
genomes of animals, plants and viruses.  
 Genomic locations of miRNAs are diverse: they may be found 
between genes, within introns or exons, and exist singularly or in 
clusters. MicroRNAs are transcribed as part of long precursor RNA 
transcripts (primary transcript: pri-miRNA) that fold on themselves to 
form hairpin-shaped structures (3). The transcription of pri-miRNA may 
be mediated by either polymerase II or polymerase III (4). Each pri-
miRNA may consist of one or more hairpin structures which will 
eventually be recognized and cleaved by the Drosha and DGCR8 
complex near the base of the stem loop to release precursor miRNA 
stem-loops (pre-miRNAs). Pre-miRNAs are exported out of the nucleus 
via an exportin-5-dependent process, recognized by ribonuclease III 
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Dicer and TAR RNA-binding protein and cleaved by Dicer to generate 
a mature miRNA duplex (5). Either strand of the duplex may be 
biologically active and is incorporated into the RNA-induced silencing 
complex (RISC) which contains a member from the Argonaute (Ago) 
family of proteins (Ago1, 2, 3 or 4). The miRNA-loaded RISC is able to 
recognize target mRNA and consequently resulting in either mRNA 
cleavage or translational repression. 
 The recognition of target mRNAs by miRNAs relies on a rather 
ambiguous level of complementarity between the miRNA and its target 
site. A minimum requirement for miRNA target recognition appears to 
be the existence of base pairing between the seed sequence of the 
RISC-loaded miRNA (2nd to 7th or 8th nucleotide from the 5’ end of 
miRNA) and its complementary seed sequence in target mRNAs. Base 
pairing between the 3’ end of a miRNA and its target site may or may 
not be necessary for translational repression to occur. Although 
Watson-Crick base-pairing is assumed by most miRNA target 
prediction algorithms, numerous miRNAs are known to utilize G:U 
wobble pairing in recognizing their targets (6). Full sequence 
complementarity between miRNAs and mRNAs are typically 
exemplified in plants while partial complementarity between miRNAs 
and mRNAs occurs most of the time in animals. While full 
complementarity results in mRNA cleavage, partial complementarity is 
known to accelerate decay of the mRNA transcripts. This is achieved 
by deadenylation, mRNA degradation or interfering with the initiation or 
elongation of translation. Messenger RNAs bound to miRNA-loaded 
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RISC may be localized to cytoplasmic compartments known as P-
bodies where they are sequestered from cytoplasmic translational 
machinery or degraded. Moreover, after the initial discovery that 
miRNAs recognize complementary sites in the 3’ UTRs of target genes, 
miRNAs have also been shown to recognize target sites residing in the 
5’ UTR as well as the coding sequence of mRNAs (6). Coupled with 
the rather low stringency for functional miRNA and mRNA interactions, 
each miRNA can regulate numerous mRNAs. 
 
1.2 MicroRNAs in glioblastoma multiforme (GBM) 
Glioblastoma mulitforme (GBM) is an aggressive primary brain tumor 
where the median time from clinical diagnosis to mortality is 
approximately one year. Since surgical resection, radiotherapy and 
chemotherapy provide patients with little improvement to their survival 
rates, there is an urgent need to develop new therapeutics with greater 
efficacy. Since microRNAs were discovered to regulate gene 
expression at the post-transcriptional level, it was not unexpected that 
pervasive dysregulation of microRNAs occur during tumorigenesis, 
leading to widespread perturbation of many biological processes. 
MicroRNAs under-expressed or absent in cancers often target 
tumorigenic genes while over-expressed microRNAs target tumor 
suppressor genes. Consequently, deregulated gene expression 
induced by altered miRNA expression has been shown to influence 
several key biological processes affecting tumor progression (7-11), 
including motility, invasion, apoptosis, cell growth, angiogenesis and 
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epithelial-mesenchymal-transition (12). Several miRNAs regulating 
gliomagenesis have been identified. A clear understanding of the exact 
contributions of microRNA to gliomagenesis will help in developing 
therapeutics targeting microRNA expression in GBM.  
 Expression of glioma-suppressive miRNAs is typically down-
regulated in GBM; re-expression of such miRNAs in gliomas presents a 
therapeutic opportunity. Consequences of microRNA expression 
therapy are often very similar, glioma cells may undergo cell cycle 
arrest, apoptosis, differentiation or diminished invasiveness and 
angiogenicity. MicroRNA-7 is one such miRNA whose re-expression 
decreases the survival, proliferation and invasiveness of cultured 
glioma cells (13). MiR-7 is known to target EGFR, an oncogenic 
receptor tyrosine kinase that is frequently amplified in GBM (13) and 
focal adhesion kinase, which regulates glioma cell invasion (14). 
Delivery of miR-31 into glioma cells down-regulates radixin and inhibits 
glioma cell migration and invasion (15). MiR-451 inhibits the PI3K/AKT 
pathway via targeting CAB39 (16), hence reducing glioma growth, 
proliferation, and invasion whilst promoting apoptosis (16, 17). In 
particular, miR-451 expression varies correspondingly with glucose 
levels (18). Under low glucose conditions, miR-451 expression 
decreases such that it no longer represses CAB39 thus stabilizing the 
LKB1 complex and phosphorylation of AMPK. This reduced 
proliferation through inhibition of mTOR but increased cell migration 
through phosphorylation of MARK. This adaptation is perceived to let 
glioma cells compromise cell proliferation in favor of more aggressive 
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invasion that will ameliorate the metabolic stress facing the glioma cells 
(18). Expression of miR-205 in glioma cells induces cell cycle arrest, 
apoptosis, viability and invasiveness. Furthermore, miR-205 targets 
VEGF-A, implying that miR-205 acts pleiotropically in suppressing 
gliomagenesis by regulating angiogenesis(19). MiR-124 and miR-137 
are highly expressed in normal brain tissues and their introduction into 
cultured glioma cells reduced cellular proliferation and induced 
neuronal differentiation (20). Similar to miR-124, pro-neuronal miR-128 
miR-128 represses growth of glioma-initiating neural stem cells via 
targeting the epithelial growth factor receptor (EGFR) and platelet-
derived growth factor receptor alpha (PDGFRA) (21). In addition to 
miR-7 and miR-128, miR-146b-5p similarly targets EGFR and miR-
146b-5p expression suppresses glioma cell invasion, migration and 
phosphorylation of Akt (22). MiR-106a suppresses proliferation and 
induces apoptosis in glioma cells via targeting E2F1 in a p53-
independent fashion (23). miR-101 is down-regulated in GBM and 
targets the histone methyltransferase EZH2 (24). Expression of miR-
101 in glioma cells in vitro attenuated glioma cell growth, migration, 
invasion and GBM-induced endothelial tubule formation (24). miR-26b 
is lowly expressed in glioma cells and re-expression of miR-26b 
diminished proliferation, migration and invasion of glioma cells in vitro 
(25). Moreover, miR-26b targets ephrin A2 and diminish the capacity of 
glioma cells in forming microvascular channels in vasculogenic mimicry 
experiments (25). Re-expression of miR-218 suppresses the invasive 
potential of gliomas, a process mediated by mir-218’s down-regulation 
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of its target protein, IKK-β, an antagonist of NF-κB activation (26). miR-
29b and miR-125a are down-regulated in GBM and their re-expression 
in glioma cells coordinately down-regulate podoplanin and 
consequently inhibit invasion, apoptosis and proliferation of glioma 
cells (27). Although numerous miRNA targets for miRNA replacement 
therapy in GBM have been identified, the hurdles facing systemic 
delivery of RNA oligonucleotides to glioma tissues remain – how 
should RNA oligonucleotides such as miRNA or siRNA be delivered to 
achieve maximum efficacy with minimum systemic toxicity.  
 As opposed to tumor-suppressive miRNAs, oncogenic miRNAs 
target an assortment of tumor suppressor genes that normally limit 
tumor cell growth, angiogenesis and motility. MicroRNA-221 has been 
shown to be over-expressed in GBM and targets tumor suppressor p27 
(28, 29) as well as pro-apoptotic PUMA (30). Moreover, miR-221 and 
miR-222 targets protein tyrosine phosphatase µ (PTPµ) which 
suppresses glioma cell migration and dispersal (31). miR-26a is 
frequently amplified in GBM at the genomic level and this amplification 
is often associated with monoallelic PTEN loss, a result of functional 
regulation of PTEN by miR-26a (32). miR-335 expression is highly 
elevated in astrocytomas and ectopic expression of miR-335 in C6 rat 
glioma cells enhances its viability, soft-agar colony forming ability and 
invasiveness (33). Silencing of miR-335 causes growth arrest and 
apoptosis as well as reduced invasion and reduced growth of 
xenografts (33). miR-381 is another candidate oncogenic miRNA that 
targets glioma suppressor LRRC4 (34). Suppressed LRRC4 
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expression enhances glioma cell proliferation in vitro and in vivo via 
decreased inhibition of MEK/ERK and AKT signaling (34). Ectopic 
expressing of miR-93 in U87 glioma cells augmented co-cultured 
endothelial cell spreading, growth and tube formation in vitro and 
promoted blood vessel formation in vivo (35). Furthermore, integrin-β8 
is a target of miR-93 and the silencing of integrin- β8 by miR-93 
enhanced glioma cell proliferation (35). miR-21 is broadly over-
expressed in many tumors including GBM (36) and its regulation of 
tumor cell motility, invasion and apoptosis have been vastly 
demonstrated (37-40). Down-regulation of miR-21 or over-expression 
of its target, programmed cell death 4 (PDCD4), decreased 
proliferation and increased apoptosis in cultured glioma cells (41). High 
expression of miR-21 also causes glioma invasion via down-regulating 
Sprouty2 and interference of the Ras/MAPK negative feedback circuit 
(42). Furthermore, silencing of miR-21 in cultured glioma cells led to 
reduced viability in murine xenografts (38, 41). Over-expression of 
miR-30e* down-regulates IκBα, leading to hyperactivation of NF-κB 
and NF-κB-regulated genes (43). Hyperactivation of NF-κB pathway 
increases the invasiveness of glioma cells.  
 A key trait of many systemic cancers is the ability to acquire the 
metastatic phenotype and colonizes distant organs away from the 
primary tumor site. MicroRNA-10b was first suggested as a pro-
metastasis miRNA via its down-regulation of HOXD10 in metastatic 
breast cancer (44); miR-10b is coincidentally the most highly over-
expressed miRNA in GBM (32, 45) even though GBM rarely 
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metastasizes out of the brain. Recent reports on the contributions of 
miR-10b to gliomagenesis, however, present conflicting findings. 
Gabriely and co-workers showed that miR-10b promotes glioma cell 
growth and suppresses cell death with no effects on glioma cell 
invasion (46), while Sun and co-workers demonstrated miR-10b does 
not affect glioma cell cycle but enhances glioma cell invasion via down-
regulation of HOXD10 and up-regulation of MMP14 and PLAUR (47). 
Further studies are needed to clarify the actual contribution of miR-10b 
to gliomagenesis. Various tools and techniques for silencing miRNA 
exist and the strengths and weakness of each approach will be 
discussed. 
 
1.3 MicroRNA Loss-of-Function Studies 
Adding to the complexity in miRNA studies is the perception that each 
miRNA can possibly regulate hundreds of target genes, a fact 
underscored by numerous published miRNA-target prediction 
algorithms (6, 48-50) that have aided miRNA target identification. 
However, every computational prediction of a miRNA target has to be 
experimentally validated, thus complicating efforts in the functional 
annotation of more than 1000 animal miRNAs known thus far. Given 
the existing scientific interest in differential gene expression in various 
biological contexts, the discovery of miRNAs led to an onslaught of 
studies that implicated miRNAs in physiological responses, 
developmental processes and disease development. Therefore, 
studies of any miRNA have to be performed in the context that it is 
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expressed in, to provide a factual mechanistic understanding of a 
miRNA’s biological contribution. Cognizant of the fact that a gene’s 
physiological expression level affects its function and activity, a loss-of-
function experimental approach allows for biologically-relevant 
discoveries of a miRNA’s function. In contrast, stemming from the 
observation that interactions between miRNA and target mRNA are 
strongly concentration-dependent, non-physiological mRNA targets 
may be repressed when exogenous miRNA is added at 
supraphysiological levels to a cellular system (51). 
Four strategies for studying miRNA loss-of-function exist: Dicer 
inactivation technology (52), genetic knockouts (53), anti-miRNA 
oligonucleotides (54, 55) and miRNA sponge or decoy technology (53, 
56-59). A quick summary of the pros and cons of each technology is 
summarized in Table 1. 
 
Table 1. Comparison of current microRNA inhibition technologies 




















Impossible Tedious Easy Very easy 
Ease of 
implementation 
Tedious Tedious Very easy Very easy 
Potential for 
therapeutic use 
Unlikely No Possible Possible 
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 Dicer is an integral part of the miRNA biogenesis pathway and 
has been a popular target for studies on global loss of miRNA function. 
Dicer inactivation allows scientists to define the requirement of miRNAs 
at the cell, tissue or system level. Various groups have utilized the 
Dicer inactivation technology to conclude that miRNAs are necessary 
and important for cell lineage decisions (60), lung development (61), 
lymphocyte development (62-64). Certain important caveats have to be 
considered in the use of this approach. One, inactivation of Dicer does 
not allow for the identification of the miRNA that are involved in any 
biological process being studied.  Two, knocking out Dicer often leads 
to embryonic lethality or early neonatal death (65-68). Three, Dicer 
inactivation in the adult heart unexpectedly resulted in an increased 
expression of a subset of microRNAs, putting the effectiveness of Dicer 
inactivation into question (69). 
On the other hand, genetic knockouts provide a powerful tool for 
a permanent, complete loss-of-function analysis of any microRNA both 
in situ at a cellular level and in a tissue-specific manner in vivo. Gene 
knockout technologies are at a mature state of development, with the 
homologous recombination method mostly used in miRNA knockout 
mice (70, 71) and the FLP-FRT deletion method in flies (72, 73). 
MicroRNA knockouts have so far been used to study the function of 
Drosophila miR-1 (72, 73), murine miR-1-2 (71), murine miR-126 (74) 
and murine miR-155 (70). Evidently, gene ablations in animals are 
largely limited to flies (72, 73) and rodents (70, 71) and impossible for 
studies in humans. As a knockout phenotype is influenced by 
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environmental and genetic factors and given some existing differences 
between the physiology of flies, mice and humans, it may not be easy 
to extrapolate findings from model organisms to humans. Another 
challenge lies in the residence of many miRNAs in protein-coding 
genes (75), hence obstructing efforts at creating clean genetic 
knockouts without creating confounding factors. An obvious 
disadvantage of the miRNA knockout approach is that some miRNAs 
belong to a family of closely related miRNAs. MicroRNA members in a 
family have the same seed sequence and are hence predicted to target 
a similar repertoire of mRNA targets; this mechanism of redundancy 
greatly diminishes any meaningful phenotypic discovery. In many 
cases, members of a miRNA family are located at different genomic 
loci, making the genetic knockout of the entire miRNA family a 
complicated, if not impossible task. 
Anti-miRNA oligonucleotides (AMOs) are antisense 
oligonucleotides which are fully complementary to the sequence of the 
miRNA being studied. AMOs may require certain chemical 
modifications to enhance hybridization stability by rendering them (i) 
resistant to cellular nucleases, (ii) resistant to cleavage after miRNA 
binding and (iii) highly effective in binding miRNA and out-competing 
endogenous mRNAs in binding to miRNA. Such chemical modifications 
include 2’-O-methyl ribose sugars (54, 55, 76), 2’-deoxynucleotides 
and locked nucleic acid nucleotides (39, 77-79), phosphorothioate 
backbone linkages (80-83) and peptide nucleic acid oligonucleotides 
(84). AMOs delivered into cells base pair efficiently with the mature 
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miRNA in the RISC complex, thus mediating a potent miRNA-specific 
loss-of-function. AMOs eventually do get degraded over time, hence an 
AMO-mediated loss of miRNA function can only be a transient event 
and provides a window of opportunity for scientists to identify miRNA 
targets that are derepressed. Frequently, AMO-mediated inhibition of 
miRNA function arise from a degradation of the target miRNA (80, 83, 
85) although in a few reports, AMOs have been found to sequester 
their target miRNAs without causing their degradation (86, 87). A few 
studies that quantified miRNA expression after AMO-mediated miRNA 
silencing found that an AMO can achieve almost full knockdown of its 
targeted miRNA (43-46). Due to the ease of design, production and 
commercial availability, AMOs have turned out to be a favorite tool of 
researchers. In particular, AMOs do not discriminate between identical 
mature miRNAs that may have arose from different genomic loci, 
hence offering an easy mode of knocking down miRNAs with multiple 
genomic copies.  
The miRNA sponge technology relies on the transcription of an 
mRNA containing several tandem target sites complementary to a 
miRNA of interest. High over-expression of the miRNA sponge favors 
its binding to the miRNA of interest, thereby hindering the miRNA’s 
ability to regulate its natural target mRNAs. A simple illustration of the 
technology is shown in Figure 1.  
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Figure 1. Principle of using microRNA sponge to inhibit endogenous 
microRNA function.  In the absence of a microRNA sponge (left), 
microRNA-loaded RNA-induced silencing complex (RISC) recognizes 
target mRNAs in the cell. Numerous copies of microRNA sponge in the 
cell (right) their binding to the target microRNA and decreases the 
probability of microRNA binding to endogenous mRNA targets. 
Translational repression exerted by the microRNA on its endogenous 
target mRNAs is relieved. 
 
The miRNA sponge technology is especially well suited for 
knocking down closely related members of a miRNA family due to their 
sharing of a seed sequence (typically between nucleotides 2-8 of the 
mature miRNA) with one or more differing nucleotides in the remaining 
miRNA sequence (88-90). We shall discuss the key considerations in 
designing an effective miRNA sponge for miRNA interference in the 
next section. It is intriguing to note that miRNA sponges, although 
thought to be entirely synthetic when it was first devised in 2007, are 
present naturally in both plants (91, 92) and animals (93) and 
represents a novel miRNA regulatory mechanism. 
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1.3.1 Considerations in MicroRNA Sponge Design 
Saturation of a highly-expressed miRNA requires high intracellular 
expression of the miRNA sponge. This supraphysiological expression 
of the miRNA sponge is dependent on primarily a few factors – the 
vector for transgene delivery, strength of promoter and the stability of 
the miRNA sponge. We shall discuss these and other variables that 
may provide insights on the optimal miRNA sponge design. 
 
Vector 
The choice of vector for delivering miRNA sponges depends on the 
experimental outcomes desired – be it short to long term transgene 
expression, spectrum of cells to be transfected or transduced and 
whether chromosomal integrations or insertional mutagenesis is a 
matter of concern. For most transient microRNA knockdown assays, 
plasmid transfection or non-integrating viral transduction at high 
multiplicity of infection is able to deliver high dose of the miRNA 
sponge transgene. While seemingly straightforward, not all cells are 
amenable to being transfected or transduced with high efficiency and 
hence, the choice of vector has to be sorted out experimentally. Non-
integrating viruses including adenovirus (53) and adeno-associated 
virus (94) have been used successfully for delivery of miRNA sponge 
while integrating viruses such as lentivirus (58) and retrovirus (95, 96) 
are used when stable transgenic cell lines are required. Of note, given 
the inability of retrovirus to transduce non-dividing cells and the ability 
of lentivirus to transduce both dividing and non-dividing cells, retroviral 
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vectors cannot be used for stable expression of miRNA sponge in non-
dividing cells such as neuronal cultures. To further ascertain that any 
cellular phenotype observed from a miRNA knockdown by retroviral or 
lentiviral vector is attributed to the miRNA and not retroviral insertion-
mediated gene disruption or mutagenesis, it will be wise to create 
multiple clonal cell lines for in vitro studies. For gene therapy 
applications utilizing a miRNA sponge as a therapeutic agent, 
adenoviral or adeno-associated viral vectors elicit an immune response 
in humans due to pre-existing immunity against adenoviruses (97), 
thus limiting its clinical utility. There is also a considerable safety risk 
with the use of retroviral vectors although there are a number of 
ongoing gene therapy clinical trials utilizing lentiviral vectors (98). The 
clinical data from those trials will provide valuable views on the clinical 
suitability and safety profile of lentiviral vectors. 
 Baculovirus has emerged as a promising class of gene delivery 
vector after seminal work that describes baculoviral transduction of 
mammalian cells (99). Baculovirus comes from a family of insect virus 
and the Autographa califarnica multiple nuclear polyhedrosis virus 
(AcMNPV) is the most commonly studied baculovirus. There are 
several advantages for using baculovirus over other animal-derived 
viruses such as retrovirus, lentivirus, adenovirus and adeno-associated 
virus. Baculovirus transduces a broad range of mammalian cells with 
no significant toxicity and do not replicate in these non-host cells (100). 
Through expression cassette engineering, baculovirus may deliver 
transgenes and attain a high level of expression in mammalian cells 
 - 28 - 
(99, 101). Another advantage that baculovirus has over animal viruses 
is its large cloning capacity that may be used to deliver several 
transgenes. Moreover, humans do not have any pre-existing immunity 
against baculovirus, hence precluding an initial prompt immune 
response against baculovirus. However, baculovirus borne in blood will 
be quickly inactivated by the complement system before transduction in 
vivo can occur (102). This limits the use of baculovirus in vivo to 
tissues or organs where exposure to serum may be avoided. This 
includes the eye (103-105), brain (106, 107) and testis (108, 109). Till 
date, the efficacy of baculoviral vectors in delivering and expressing 
miRNA sponge has yet to be determined. 
 
Promoter 
The expression cassette of a miRNA sponge comprises of a 
transcriptional regulatory element such as a promoter, a reporter gene 
for monitoring the sponge’s efficacy, and miRNA binding sites in the 3’ 
untranslated region of the reporter gene. A diagram of a typical miRNA 
sponge design is shown in Figure 2.  
  
Figure 2. Design of an expression cassette harboring a microRNA 
sponge. Several binding sites that are fully or partially complementary 
to the sequence have been used successfully by several research 
groups to inhibit microRNA function. A reporter gene such as eGFP or 
luciferase is commonly used to gauge expression level of the 
microRNA sponge. 
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A strong promoter augments the vector in driving high expression of 
the miRNA sponge for effective miRNA knockdown. Such a strong 
promoter is usually of viral origin such as the CMV promoter (53, 56) 
and viral long terminal repeats (LTRs) (95, 110). RNA polymerase III-
driven promoters such as the U6 promoter, had also been used 
successfully to express transcripts harboring miRNA target sites that 
mediated effective miRNA knockdown (57, 59, 111, 112). Choosing 
any of the above-mentioned promoters should ensure sufficient 
expression of the miRNA sponge for efficient miRNA inhibition. 
However, the true efficacy of the sponge design still has to be tested 
experimentally. Furthermore, the viral CMV promoter may face 
transcriptional silencing due to promoter methylation (113). Therefore, 
the persistence of the sponge expression should be monitored 
periodically especially for long term studies. This problem can be easily 
circumvented with the use of a reporter gene such as enhanced green 
fluorescent protein or firefly luciferase protein which allows for easy 
monitoring of the miRNA sponge expression both in vitro and in vivo. 
 
Reporter Gene 
Other than providing an easy way to monitor miRNA sponge 
expression temporally and spatially, the reporter gene provides a 
useful means of monitoring the effectiveness of the miRNA sponge. In 
most instances, the reporter gene is appended upstream of the miRNA 
sponge and an accumulation of the reporter protein hints at the 
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saturation of the miRNA sponge with the target miRNA. Given the 
focus on ensuring supraphysiological expression levels of the miRNA 
sponge, a reporter gene that possesses minimum toxicity at high 
expression level is desired. Destabilized eGFP (58, 110, 114), eGFP 
(53, 56, 115, 116), YFP (117) and mCherry (112, 118) have been 
successfully used in providing researchers with easy identification of 
cells expressing the tethered miRNA sponge. A drug resistance marker 
co-expressed with the fluorescent reporter allows for selection of 
clones that highly expressed the miRNA sponge. This selection 
process can be aided by the use of fluorescence-activated cell sorting 
to identify the clones that highly express the miRNA sponge. The 
diversity of fluorescent reporter genes available may conceivably allow 
some small scale multiplexing of miRNA sponge expression, with 
different fluorescence wavelengths representing different miRNA 
sponges. Firefly luciferase reporter gene potentially allows researchers 
to identify the location and monitor the temporal expression of the 
miRNA sponge in small animals such as rodents. 
 
MicroRNA Binding Sites 
In animal systems, mRNA transcripts containing binding sites that are 
perfectly complementary to the miRNA are suppressed to a greater 
extent than those harboring partially complementary binding sites. This 
observation is unlikely to be related to the miRNA’s recognition of its 
target site since the seed sequence of a miRNA (2nd to 8th nucleotide of 
the miRNA) is the primary determinant of miRNA:mRNA targeting (48, 
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119, 120). Instead, current evidence points to the existence of two 
mechanisms for miRNA regulation of its target mRNAs. MicroRNAs in 
the RNA-induced silencing complex (RISC) are intimately associated 
with Argonaute 2 (Ago2), a ribonucleoprotein that mediates the 
cleavage of mRNA targets recognized by the Ago2-associated miRNA. 
This Ago2-mediated cleavage occurs in the presence of complete base 
pairing between the miRNA and its binding site, more precisely, 
between mRNA nucleotides that pair to the 10th and 11th nucleotide of 
the miRNA (54, 121, 122). When incomplete base-pairing occurs 
between the miRNA and its binding site at positions 9 to 12, Ago2-
mediated cleavage is impaired. mRNA destabilization and translational 
repression occurs in this event , a process thought to be facilitated by 
the shortening of the RNA transcript’s poly (A) tail (123). Consequently, 
incomplete base-pairing is thought to result in the continued binding of 
the miRNA-loaded RISC to its target mRNA, thus lowering the 
availability of the miRNA for regulation of its other natural targets.  
 Bearing these lessons in mind, microRNA binding sites that are 
partially complementary to target miRNA have been used effectively 
and successfully to decoy miRNA away from its natural targets (57-59). 
A comparison of perfectly and partially complementary miRNA binding 
sites showed that, at a low concentration of miRNA binding sites, 
partially complementary miRNA binding sites were more effective at 
saturating miRNAs than perfectly complementary miRNA binding sites 
(58). For the record, several studies have demonstrated the 
effectiveness of perfectly complementary miRNA binding sites as a 
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miRNA sponge (53, 56-59, 111, 112, 124). This can be possibly 
explained by the high expression of the miRNA binding sites to a point 
of saturation which eventually negates the advantage that partially 
complementary miRNA binding sites has over perfectly complementary 
miRNA binding sites (58). Another explanation could be that miRNAs 
that were complexed with the catalytically inactive Ago 1, 3 or 4 can 
still be targeted by the miRNA sponge without any consequential 
sponge degradation. In light of this finding, researchers interested in 
gene delivery in vivo may fare better to utilize partially complementary 
miRNA binding sites driven by a tissue-specific promoter that provides 
tissue-specific expression albeit with lower expression strength than 
viral promoters. An illustration of what exactly constitutes perfect and 
imperfect complementarity of a miRNA binding site for its cognate 
miRNA, e.g. miR-10b, is shown in Figure 3. 
 
Figure 3. Illustration of the sequence of a microRNA-10b binding site 
that is fully complementary to microRNA-10b (top), and a modified 
microRNA-10b binding site that is partially complementary to 
microRNA-10b through mismatches to nucleotides 9 to 12 of 
microRNA-10b. 
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 The number of miRNA binding sites influences the effectiveness 
of a miRNA sponge in regulating miRNA (1, 120, 125). An increase in 
the number of miRNA binding sites presumably improves the chance 
for its recognition by miRNA and enhances the level of miRNA-
mediated suppression (125, 126). Most studies have constructed 
miRNA sponges containing four to sixteen miRNA binding sites while a 
handful have reported successful miRNA inhibition using one to three 
miRNA binding sites. One has to be mindful of the balance between 
increasing the number of miRNA binding sites and the increased 
likelihood of miRNA sponge degradation and empirically determine the 
number of miRNA binding sites that work.  Till date, no study has 
clearly demonstrated the minimum spacer requirement in between 
each miRNA binding site for effective miRNA decoy although most 
studies have utilized a length of a few nucleotides successfully. As with 
any well-controlled experiment, variations in the mismatches of the 
partially complementary miRNA binding sites as well as spacer lengths 
can be introduced into the miRNA sponge design, so as to rule out the 
introduction of recognition motifs for other RNA regulatory factors. 
 Other than the number and type of miRNA binding site adopted 
in a miRNA sponge, the stability of the sponge and its accessibility to 
miRNAs are important issues to be considered. While RNA 
Polymerase II-generated transcripts are rather stable due to the 
presence of a 5’ cap and 3’ poly (A) tail, RNA Polymerase III-generated 
miRNA sponges lack those features and their stability can be 
enhanced by the inclusion of terminal stem loops (57). Other than the 
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length of the spacer sequence between miRNA binding sites which 
may affect the accessibility of miRNA sponge to its target miRNAs, 
positioning of miRNA binding sites within the expression cassette 
affects its accessibility to miRNAs as well. The coding region of a 
mRNA is continually accessed by ribosomal machinery and certain 
untranslated regions of a mRNA transcript may contain secondary 
structure. Hence, miRNA binding sites should be placed in the non-
coding region of the RNA transcript and in a region that has no known 
secondary RNA structure.  
 
1.3.2 Advantages and Limitations of MicroRNA Sponge over Other 
MicroRNA Loss-of-Function Strategies 
Although miRNA genetic knockouts are the only sure way of ensuring 
complete loss of miRNA activity and identifying its function, a vector-
based miRNA sponge strategy addresses some of the shortcomings of 
the genetic knockout approach. MicroRNA sponge has broad 
applicability to a wide range of model organisms and cell lines, 
including potential gene therapy applications in humans. MicroRNA 
knockouts are however limited to a few model organisms such as the 
mouse and the fly, and are relatively more tedious to obtain then a 
miRNA sponge. To exacerbate the challenges in miRNA knockout, 
approximately over a third of miRNA genes reside in protein-coding 
genes, making it impossible to knockout the miRNA without creating a 
confounding factor (75). The same issue occurs for miRNA precursors 
that are located close to one another and transcribed in clusters. The 
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proximity of miRNAs to one another within a cluster complicates efforts 
at deleting one miRNA without affecting the transcription or processing 
of other miRNAs in that same cluster. Many miRNAs are part of miRNA 
families, where each family member harbors the same seed sequence. 
If a single miRNA gene is knocked out, other alleles of the same 
miRNA or other miRNAs from the same miRNA family may display 
some compensatory effect. Knocking out all alleles of a miRNA or 
associated miRNA family members, which are often located at multiple 
and distant genomic loci, will be extremely tedious and the animals 
have to be bred repeatedly to generate a multiple miRNA-knockout 
strain. In reality, given the important role of miRNAs in almost all 
aspects of physiology, embryonic lethality may arise and a multiple 
miRNA-knockout effort may not come to fruition. Since a miRNA 
sponge expresses miRNA binding sites that can be recognized by any 
miRNA with the same complementary sequence (example, multi-allelic 
miRNAs) or complementary seed sequence (example, entire miRNA 
family with the same seed sequence (56, 57, 127)) and inhibits the 
function of the mature miRNA without the need for host genomic 
modification, it is able to bypass the above-mentioned issues and 
challenges associated with traditional gene knockout techniques. While 
the miRNA sponge approach does not allow for the study of a loss of 
function of the individual miRNA family member, this limitation may be 
sufficiently ameliorated by the identification of target mRNAs that are 
commonly regulated by the miRNA family (56) since miRNA family 
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members are predicted to regulate a similar repertoire of target mRNAs 
(119). 
 Anti-microRNA oligonucleotides (AMOs) offer a fast and 
convenient way of assaying the function of a single miRNA. While a 
miRNA sponge may be able to antagonize the function of a miRNA 
which is not part of a miRNA family, it inevitably inhibits the entire 
miRNA family when the target miRNA shares the same seed sequence 
with other miRNAs in the family. In this way, use of a miRNA sponge 
for knocking down of an entire miRNA family is more advantageous 
than the use of a cocktail of AMOs for inhibiting a family of miRNAs. 
Moreover, many cell types are resistant to transfection in varying 
degrees, rendering the delivery of AMOs difficult. This limitation can be 
overcome with the use of an appropriate viral vector that transduces 
target cells easily and consequently expresses the miRNA sponge. 
AMOs act transiently in their inhibition of miRNA function and would 
require multiple administrations for long-term knockdown studies. A 
miRNA sponge, based on lentiviral vector delivery, offers the chance of 
stable miRNA knockdown without repeated administrations (56, 58, 
124). The lentiviral based miRNA sponge allows for the creation of 
miRNA sponge-expressing animals to continually inhibit the miRNA of 
interest for the animal’s lifetime. This can be further enhanced through 
the inclusion of drug-inducible regulatory elements or tissue-specific 
promoters for temporal and spatial knockdown of miRNA function in 
vivo. In contrast, AMOs injected systematically into mice could not 
enter all tissues and largely accumulate in the liver (80). 
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 MicroRNA sponge technology is not without its limitations. 
Certain cells or tissues may not be permissive to viral transduction or 
may not allow for strong expression of the miRNA sponge transcript. In 
those scenarios, weak expression of the miRNA sponge may not be 
able to consequentially saturate the target miRNA. If high expression of 
miRNA sponge is achievable, one must be mindful of any toxicities 
arising from high over-expression of the reporter gene. It remains 
challenging to assess if the miRNA sponge technology is effective 
given a lack of knowledge of the miRNA’s natural targets. Even if a 
miRNA’s natural mRNA target is known but was deduced from a 
different cellular context, the mRNA of interest may not be co-
expressed with the miRNA in another cellular context. To overcome 
this, a useful approach will be to use a ‘miRNA sensor’ construct to 
determine the level of miRNA inhibition achieved by miRNA sponge 
over-expression (57-59, 126). Nonetheless, once the efficacy of a 
miRNA sponge is validated with well-controlled studies, the benefits of 
using a miRNA sponge may outweigh the hassles associated with 
using it. 
 
1.3.3 Interrogating MicroRNA Function via Transient MicroRNA 
Sponge Expression 
Transient but strong expression of miRNA sponges has been found to 
be sufficient for the initial application of miRNA sponges in vitro and in 
vivo. Ebert et al. (57) did seminal work proving that plasmid 
transfection of miRNA sponges was sufficient to result in functional 
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inhibition of miRNAs in mammalian cell lines, at least with the same 
efficacy as the use of anti-miRNA antisense oligonucleotides. 
Extrapolating this technology in vivo with the use of viral vectors for 
gene delivery, Care et al. (53) administered adenoviral vectors 
expressing miR-133 sponge trans-coronarily to mouse cardiac 
myocytes and noted a significant increase in left ventricular size after 
the inhibition of miR-133. Key findings from those two research groups 
provide a guideline for design of miRNA sponges in both in vitro and in 
vivo applications. In terms of gene delivery, transfection works in a 
quick and fuss-free manner for researchers to suss out important 
biological information in vitro. However, for efficient gene delivery in 
vivo, viral vectors such as adenovirus are needed. The range of cells 
types available for miRNA functional investigation is only limited by its 
propensity to be transfected or transduced. MicroRNA sponge 
techniques have been amply demonstrated in various plant, human, 
mouse and rat cells (53, 57, 91, 111). Strong transcriptional regulatory 
elements such as the cytomegalovirus (CMV) promoter (57), U6 
promoter (111), and long terminal repeats (LTRs) (127) have been 
used to mediate successful miRNA inhibition.  The key to ensuring that 
transient miRNA sponge expression is effective is to perform 
derepression assays 24 hours to 72 hours after delivery of the miRNA 
sponge. At its peak of expression, the miRNA sponge should be able to 
decoy sufficient miRNA away from its endogenous targets. This 
derepression can be assessed by investigating the mRNA or protein 
expression of a miRNA target if such a target has been previously 
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reported. However, in some cellular contexts such as cancer cells 
where genomic deletions are abundant, the target mRNA of interest 
may not be expressed. This necessitates the development of a miRNA 
sensor construct (57, 58) which essentially comprises a reporter gene 
and the cloning of a single complementary miRNA binding site in the 3’ 
untranslated region of the reporter gene. In the presence of the miRNA, 
reporter gene expression is silenced; with an increasing dosage of 
miRNA sponge, functional inhibition of miRNA leads to re-expression of 
the reporter gene. Reassuring was the finding that transient expression 
of miRNA sponge results in a significant reduction of the mature 
miRNA levels (111, 128, 129), which may be suggestive of a miRNA 
degradation activity. However, Ebert et al. (57) discovered some 
mature miRNA signal at a position on the Northern blot where the 
reporter gene was even though the mature miRNA was not detected 
after miRNA sponge expression, hinting that the total concentration of 
the miRNA may not have changed but the amount of free and active 
mature miRNA may have decreased drastically after sequestration by 
the miRNA sponge. 
 
1.3.4 Interrogating MicroRNA Function via Stable MicroRNA 
Sponge Expression 
Continuous expression of a miRNA sponge allows researchers to 
conduct long-term studies of miRNA loss-of-function in vitro and in vivo. 
In vivo studies involving, for example, bone marrow reconstitution 
typically require a period of time for cell repopulation and expansion. 
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Such studies will be impossible to perform using transient techniques 
of knocking down miRNA expression. Stable miRNA sponge 
expression is typically achieved by chromosomal integrations mediated 
by retroviral or lentiviral delivery. Although chromosomal integrations 
can possibly bring about confounding variables, it is potentially less of 
an issue if multiple clonal lines are selected and studied. The bigger 
challenge lies in the delivery of viral genome to the target cells; low 
vector copy number may not result in high miRNA sponge expression, 
thereby jeopardizing the success of the experiment. On an 
encouraging note, several groups have observed clear, albeit weaker, 
phenotypes with partial miRNA knockdown. 
 
1.3.5 Elucidation of MicroRNA Function in Cancer Development 
Deregulated expression of miRNAs in several diseases such as cancer 
has been established by several studies but the contributions of many 
of those miRNAs remain to be confirmed. Stable expression of a 
miRNA sponge has been used by many groups for such studies. 
Valastyan et al. (110) screened a panel of normal and metastatic 
mammary lines for differential miRNA expression and identified miR-31 
as lowly expressed in aggressive metastatic cancer. The authors made 
use of retroviral vectors that express eGFP miRNA sponges against 
miR-31 or a control sequence. Utilizing non-metastatic miR-31-
expressing breast carcinoma cells, silencing of miR-31 caused the in 
vivo tumor to strongly metastasize to the lungs, forming approximately 
ten times more cancerous lung lesions than with the control sponge. 
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An advantage provided by the fluorescent reporter gene tethered to the 
miR-31 sponge used in this study was the easy identification of lung 
lesions by fluorescence imaging. Moreover, miR-31 did not affect 
primary tumor size, indicating a direct and specific regulation by miR-
31 on the cancer cell’s invasive ability – more specifically, the ability of 
the cells to extravasate, invade, survive at a distant site and colonize 
secondary metastatic sites. This wide-ranging role of miR-31 stems 
from its ability to regulate a plethora of pro-metastatic genes including 
RhoA. A similar study on breast cancer metastasis allowed Ma et al. 
(79) to identify miR-10b as a highly upregulated miRNA in metastatic 
breast cancer. The authors, in a subsequent study (95), utilized 
retroviral vectors expressing miR-10b sponge to knockdown miR-10b 
function in metastatic 4T1 cells. The authors observed a 62% reduction 
in miR-10b levels and over 90% reduction in lung metastases with no 
effect on the primary mammary tumor development, once again 
confirming a role for miR-10b in breast cancer metastasis but not 
growth.  
 In extreme instances when the under-expression of miRNAs is 
due to genomic deletions, miRNA sponges may faithfully replicate 
those pathological conditions without the hassle of creating genetic 
knockouts. For instance, a region on chromosome 13q14 harboring 
miR-15a and miR-16 is frequently deleted in prostate cancer, leukemia 
and other cancers (56, 114, 118). Bonci et al. (56) used lentiviral 
vectors expressing GFP tethered to two binding sites with full 
complementarity to miR-15a (and partial complementarity to miR-16). 
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Delivering the lentiviral vector into untransformed prostate cell line 
RWPE-1 and primary tumor prostate cells, the authors showed that 
both cell types displayed an increase in proliferation rates, enhanced 
anchorage-independent growth, and pronounced increased migration 
and invasion in cancer fibroblast-conditioned medium. Interestingly, 
knockout of miR-15a and miR-16 allowed the non-tumorigenic RWPE-1 
prostate cells to form slow-growing tumors in NOD-SCID mice. The 
molecular targets of miR-15a and miR-16 are CCND1, WNT3A and 
BCL2, thus explaining the growth suppressive effects witnessed by the 
reconstitution of miR-15a and miR-16.  
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Vector Promoter Reporter 
Gene 
MicroRNA Binding Sites Target MicroRNAs Cells types Ref 
Plasmid DNA CMV d2eGFP Four to nine bulged sites miR-16, miR-20,  
miR-21, miR-30-5p 
Mammalian cell lines (57) 
Plasmid DNA U6 None Four to nine bulged sites miR-16, miR-20 Mammalian cell lines (57) 
Plasmid DNA MSCV 5’ LTR None Six to nine bulged sites Let-7, miR-16 Lung cancer line (130) 
Retroviral RCAS(A) LTR MS2, eGFP Eight bulged sites miR-155 B cell lymphoma (96) 
Retroviral pBABE 5’ LTR d2eGFP Seven bulged sites miR-31 MCF7-Ras breast cancer 
line 
(110) 
Retroviral pBABE 5’ LTR d2EGFP Eight bulged sites miR-9, miR-10b 4T1 breast cancer line (95) 
Lentiviral CMV eGFP Two perfect sites miR-15a Human prostate cell lines (56) 
Lentiviral CMV d2eGFP Seven to nine bulged sites miR-16 Multiple myeloma lines (49) 
Lentiviral U6 None One to two perfect sites miR-21, miR-140-3p, 
miR-140-5p 
Mammalian cell lines (59) 
Table 2. Recently developed microRNA sponge constructs and their applications in cancer biology
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1.4 Key Signaling Pathways Dysregulated in Glioblastoma 
Multiforme 
Numerous genetic alterations are known to occur in several key signal 
transduction pathways that have special importance to the etiology of 
glioblatoma multiforme (GBM). Notably, The Cancer Genome Atlas 
Research Network provided evidence that common alterations in GBM 
genomes impact three major signaling pathways. These pathways will 
be discussed below, with an emphasis on their significance to the 
development of GBM. 
 
1.4.1 Genetic Alterations occurring in the Receptor Tyrosine 
Kinase (RTK) Pathways 
Alterations to the genomic sequence of GBM tumors or copy number 
changes affect several components of the RTK/Ras/PI(3)K signaling 
pathways (Figure 4). Notably, EGFR mutations and amplification occur 
in 45% of GBM tumors while PDGFRA amplification occurs in 18% of 
GBM tumors sequenced by The Cancer Genome Atlas (TCGA) (45). 
Showing the significance of this complex network of genes, 88% of all 
GBM samples examined had somatic alterations in at least one 
component gene in the RTK/Ras/PI(3)K signaling network. Key tumor 
suppressors negating the activation of the RTK/Ras/PI(3)K pathways 
are often mutated or deleted as well. NF1 and PTEN are altered in 
18% and 36% of GBM respectively. Ras guanosine triphosphate (GTP) 
levels are high in GBM in the absence of mutations affecting Ras (131). 
This suggests the Ras signaling pathway is activated either by 
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upstream receptor tyrosine kinases such as EGFR, or by mutational 
inactivation or loss of the neurofibromatosis 1 (NF1) gene. NF1 
converts Ras-GTP to Ras-GDP via NF1’s GTPase-activating domain. 
More definitively, TCGA’s analysis confirmed that NF1 is frequently 
mutated or deleted in GBM (45), hence providing an additional route for 
activation of Ras signaling in GBM. Mutation of tumor suppressor gene 
phosphatase tensin homology (PTEN) is highly frequent and occurs in 
36% of GBM tumors surveyed by TCGA (Figure 4) (45). PTEN 
contains a core phosphatase domain that dephosphorylates 
phosphatidylinositol-3,4,5 triphosphate (PIP3) and  
phosphatidylinositol-3,4 diphosphate (PIP2). Mutational inactivation or 
low expression of PTEN results in elevated levels of PIP3 which is 
used by PI(3)K to phosphorylate Akt. Consequently, loss of functional 
PTEN expression results in uncontrolled cell growth via the 
hyperactivation of the PI(3)K/Akt pathway.  
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Figure 4. Genomic sequence alterations and copy number changes for 
components of the RTK/Ras/PI(3)K network of genes are shown. Red 
and blue represent activating and inactivating alterations respectively. 
Darker color shades represents higher frequency of genetic alterations.  
(Reprinted by permission from Macmillan Publishers Ltd: Nature, The 
Cancer Genome Atlas Research Network, Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. 
2008 Oct 23;455(7216):1061-8., copyright 2008) 
 
1.4.2 Genetic Alterations occurring in TP53 Tumor Suppressor 
Pathway 
Majority of GBMs also display inactivating mutations and genetic 
alterations in the TP53 pathway; as much as 87% of GBM tumors 
examined by TCGA had at least one affected component gene in the 
TP53 signaling network (Figure 5) (45). TP53 is a transcription factor 
that is upregulated in response to cellular stress such as DNA damage 
and exposure to radiation or toxins. After DNA damage, TP53 initiates 
transcription of p21 (CIP1/WAF1) to induce cell cycle arrest. This 
process may be promoted by the expression of p14ARF which blocks 
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ubiquitin-mediated decay of TP53, or negated by Mdm2 which 
degrades TP53 (132). In the TP53 signaling network, CDKN2A (p14ARF) 
and TP53 loci are frequently mutated or deleted in GBM (49% and 35% 
respectively), resulting in a significant loss of control over cellular 




Figure 5. Genomic sequence alterations and copy number changes for 
components of the TP53 network of genes are shown. Red and blue 
represent activating and inactivating alterations respectively. Darker 
color shades represents higher frequency of genetic alterations.  
(Reprinted by permission from Macmillan Publishers Ltd: Nature, The 
Cancer Genome Atlas Research Network, Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. 
2008 Oct 23;455(7216):1061-8., copyright 2008) 
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1.4.3 Genetic Alterations occurring in RB1 Tumor Suppressor 
Pathway  
RB1 inhibits E2F1 and controls cell cycle G1 to S phase progression. 
The CDK4/cyclin D1 complex phosphorylates and antagonizes RB1 
action, hence promoting the release of E2F1 and cell cycle progression. 
However, p16INK4A may bind to CDK4, inhibit formation of the 
CDK4/cyclin D1 complex, and restrict cell cycle progression (133). 
Given that p16INK4A and p14ARF are alternative splice variants of the 
CDKN2A locus, mutations or deletions affecting the CDKN2A locus 
deregulates both TP53 and RB1 signaling pathways, thus promoting 
gliomagenesis. In fact, up to 50% of GBM tumors have homozygous 
deletions which simultaneously affect the reading frames of both splice 
variants (134). As evident from TCGA’s analysis, 78% of all GBM 
tumors examined exhibit at least one altered component gene in the 
RB1 signaling pathway (Figure 6). 
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Figure 6. Genomic sequence alterations and copy number changes for 
components of the RB1 network of genes are shown. Red and blue 
represent activating and inactivating alterations respectively. Darker 
color shades represents higher frequency of genetic alterations.  
(Reprinted by permission from Macmillan Publishers Ltd: Nature, The 
Cancer Genome Atlas Research Network, Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. 
2008 Oct 23;455(7216):1061-8., copyright 2008) 
 
Although genetic alterations of tumor suppressor genes are already 
prevalent in GBM, we should keep in mind that GBM tumors 
expressing normal tumor suppressor mRNA transcripts may coexpress 
oncogenic miRNAs that prohibit the translation of the tumor suppressor 
mRNA transcripts. This additional layer of regulation of gene 
expression by miRNA may be used by a developing glioma cell’s 
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Chapter 2: Aims and objectives 
In this study, we wish to clarify the role of miR-10b in glioblastoma 
multiforme (GBM) development and validate its utility as a therapeutic 
target for GBM gene therapy. Due to the poor prognosis and lack of 
effective therapies for GBM (136), The Cancer Genome Atlas (TCGA) 
research network performed a multi-faceted molecular and genomic 
analysis on over 200 GBM specimens (45), generating a valuable 
repository for understanding gliomagenesis and developing targeted 
therapeutics. More recently, TCGA’s wealth of data has been 
deconvoluted to highlight the existence of four different subgroups, 
namely the classical, mesenchymal, neural and proneural subgroups, 
even within a pathologically uniform group of GBM (137). This raises 
the question of whether an oncogenic microRNA that is widely up-
regulated in GBM, for example miR-10b,  plays the same role in all four 
subgroups of GBM, with each GBM subgroup possessing a unique 
gene expression signature (137). 
MicroRNA-10b has been extensively studied in several 
pathologies (44, 46, 47, 138-140) and several studies have identified 
miR-10b as highly upregulated in human glioblastoma tumors as 
compared with normal brain tissues (46, 47, 141). Although miR-10b 
plays a contributing role to breast cancer metastasis (44), conflicting 
evidence has arisen with regards to miR-10b’s role in glioblastoma 
etiology (46, 47). Gabriely et al (46) showed that miR-10b regulates 
GBM growth and death in vitro and in subcutaneous U87 tumors but 
does not regulate in vitro GBM cell migration and invasion, while Sun et 
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al. (47) showed that miR-10b regulates glioblastoma cell invasion but 
not cell growth in vitro. We speculate that deficiencies in the in vitro 
tumor models used in those studies may account for their conflicting 
findings. Commonly used GBM cell lines form well-circumscribed and 
poorly invasive orthotopic tumors that do not resemble human GBM. 
Several groups have endeavored to improve the orthotopic GBM 
xenograft model. In particular, CD133-positive ‘cancer stem cells’ from 
glioblastoma tumors produced highly invasive and angiogenic 
orthotopic tumors in mice (142) while experimental lung metastasis 
assays enrich for metastatic GBM cells that produce highly invasive 
and angiogenic orthotopic tumors (143). Subjecting U87 cells – a 
commonly used human glioma cell line - to an experimental lung 
metastases assay (143), we established a subline of U87, resembling 
the mesenchymal subgroup of GBM, which we termed U87-2M1. We 
decided to use baculoviral vectors, which display high transduction 
efficiency in glioma cells (144), to construct miR-10b decoy vectors to 
study miR-10b’s functions in U87-2M1 cells. With our invasive tumor 
model, we hope to resolve the current conflicting findings on miR-10b’s 
role in GBM via transcriptional profiling of U87-2M1 cells after miR-10b 
silencing and investigation of several GBM-related processes such as 
tumor growth, programmed cell death, invasion and angiogenesis.  
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Chapter 3: Materials and methods 
Cell culture 
U87, U251, U138, SW1088 and T98G were obtained from American 
Type Culture Collection. Normal human astrocytes (NHA) and human 
umbilical venous endothelial cells (HUVEC) were from Lonza. U87-
2M1 was derived from U87 cells via an experimental lung metastasis 
assay as described (143) and propagated in vitro under hypoxic 
conditions. For hypoxia maintenance, cells were grown in a gas 
chamber that can be periodically flushed with a gas mixture of 94% 
nitrogen, 5% carbon dioxide and 1% oxygen. 
 
Baculovirus preparation 
Oligos harboring 13 repeats of a miR-10b binding site or control 
binding site were synthesized, phosphorylated, annealed and ligated 
downstream of a CMV-eGFP cassette. Recombinant baculoviral 
vectors were generated using the Bac-to-Bac baculovirus expression 
system (Life Technologies). Transduction of glioma cells were 
performed at a multiplicity of infection of 200. 
 
Intracranial and subcutaneous human glioma models 
All animal experiments were approved by an Institutional Animal Care 
and Use Committee. To analyze the difference between U87 and U87-
2M1 orthotopic growth trends, 2x105 U87-2M1 or U87 cells were 
inoculated intracranially in Balb c/nude mice. After 3 weeks of tumor 
growth, brain tissues were sectioned and H&E staining was performed. 
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To elucidate the effects of miR-10b silencing on intracranial growth of 
U87-2M1 cells, 2x105 U87-2M1 cells transduced with either control 
decoy vector or miR-10b decoy vector were injected into the left and 
right striatum respectively in five Balb c/nude mice. Brain tissues were 
collected after 3 weeks of tumor growth. H&E staining or CD31 (Abcam) 
immunohistochemical staining was performed subsequently. 
Subcutaneous U87-2M1 tumors were established by injecting 2x106 
cells into the subcutaneous space. 108 plaque-forming-units of control 
or miR-10b decoy baculoviral vectors were injected into the 
subcutaneous tumors. For survival analyses, U87-2M1 cells in vitro 
were either untransduced (PBS added) or transduced with control 
decoy vector or miR-10b decoy vector at multiplicity of infection of 200. 
Each mouse in the 3 groups of 10 mice was inoculated intracranially 
with 2x105 U87-2M1 and monitored every day for signs of moribundity. 
 
Microarray and data analysis 
Gene expression profiling was performed on the Genechip Human 
Genome U133 Plus 2.0 platform (Affymetrix, Santa Clara, CA) in 
accordance with the manufacturer’s protocol. Statistical analyses and 
data normalization were carried out using the Genespring GX software 
(Agilent). Genes with fold change greater than 2 fold were deemed to 
be differentially expressed between U87-2M1 and U87 cells. Genes 
with fold change greater than 1.5 fold were deemed to be differentially 
regulated by miR-10b silencing in U87-2M1 cells. All microarray data 
discussed in this publication have been deposited in NCBI’s Gene 
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Expression Omnibus and are accessible through GEO Superseries 
accession number GSE35208.  Gene ontology categories were 
analyzed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) version 6.7 (145, 146). 
 
Western blot analysis 
Protein samples from cell lysates were separated on a 4-12% NuPAGE 
Bis-Tris denaturing gel (Life Technologies). The following antibodies 
from Santa Cruz were used: anti-Fibronectin (1:200), anti-Twist (1:200), 
anti-Snai1 (1:200), anti-Snai2 (1:200), anti-MMP13 (1:200), anti-
FOXM1 (1:200), anti-PLAUR (1:200), anti-β-catenin (1:200), anti-IL8 
(1:200), anti-TP53 (1:200), anti-PTEN (1:200), anti-MMP2 (1:200), anti-
Ptch1 (1:200), anti-Cyclin B1 (1:200), anti-Cyclin E1 (1:200), anti-Cyclin 
D1 (1:200); from BD Pharmingen: anti-E-cadherin (1:1000), anti-N-
cadherin (1:1000), anti-VEGF (1:1000); from Abcam: anti-β-Actin 
(1:1000), anti-Vimentin (1:1000), anti-CTGF (1:1000), anti-THBS1 
(1:1000), anti-HOXD10 (1:1000), anti-Notch1 (1:1000); from Cell 
Signaling: anti-Stat3 (1:1000), anti-Cleaved Caspase-3 (1:1000), anti-
Cleaved Caspase-7 (1:1000), anti-Bim (1:1000), anti-TP53-S15 
(1:1000), anti-TP53-S20 (1:1000), anti-p21 (1:1000), anti-FOXO3 
(1:1000), anti-FOXO3-S253 (1:1000), anti-CYLD (1:1000), anti-NFκB 
(1:1000); from Novus Biologicals: anti-HGF (1:1000), anti-PLAU 
(1:1000), anti-TGFB2 (1:1000), anti-PAX6 (1:1000) and from Abnova: 
RhoC (1:1000). Western blot data shown is reflective of three biological 
replicates.  
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MicroRNA quantification 
Total RNA was extracted using TRIzol (Life Technologies) and 
microRNA quantification was performed using the Taqman microRNA 
reverse transcription and Taqman microRNA assays according to 
manufacturer’s instructions (Life Technologies). Normalization was 
performed to RNU6B. 
 
Invasion assay 
U87-2M1 glioma cells were either transduced with the control or miR-
10b decoy vectors (for miR-10b inhibition studies), or transfected with 
negative control siRNA (Qiagen) or miR-10b mimic (Qiagen) (for miR-
10b over-expression studies) for 24 hours. Invasion assays were 
performed using 24-well Matrigel-coated transwell chambers. Cells 
were resuspended in medium without serum and 5x104 cells seeded 
into each transwell chamber. Cells that invaded through the membrane, 
towards the serum-containing medium in the bottom chamber, were 
imaged and counted. Differences in cell invasion were expressed 
relative to control treatment. Images shown are reflective of four 
biological replicates performed. 
 
Endothelial cell tube formation assay 
Matrigel was added into each well of a 96-well plate and polymerized 
for 1 hour at 37oC.  Human umbilical vein endothelial cells (HUVEC) 
were harvested and 2.5 x 104 HUVEC were added to 100μl of 
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conditioned medium from 3x105 U87-2M1 glioma cells. HUVEC were 
allowed to incubate for 24 hours at 370C and cultures were 
photographed under a bright-field microscope. Images are reflective of 
three biological replicates. 
 
MicroRNA target prediction 
The longest transcripts for TP53 (variant 1), Notch1, Ptch1 (variant 1b), 
Pax6 (variant 1), FOXO3 (variant 1) and CYLD (variant 1) were 
retrieved from NCBI’s ‘Nucleotide’ database and subjected to 
screening by rna22 (6) for miR-10b binding sites. We did not allow for 
any unpaired bases in a seed of 6 nucleotides and specified for a 
minimum of 10 paired-up bases in the heteroduplex. A maximum 
folding energy of -15Kcal/mol was permitted. 
 
Cell cycle analyses 
Three days following transduction, attached and floating U87-2M1 cells 
were collected for propidium iodide staining and analyzed on the LSRII 
flow cytometry analyzer (BD Biosciences). Flow cytometric plots are 
reflective of three biological replicates. 
 
Cell viability and caspase assay 
U87-2M1 cells were transduced in 96-well plates and assayed for their 
viability three days later using CellTiter96 AQueous One Solution Cell 
Proliferation Assay (Promega). Caspase-3 and caspase-7 activities 
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Luciferase reporter constructs and target validation  
Predicted microRNA target sites, including seven nucleotides flanking 
each site, were synthesized as DNA oligomers, phosphorylated, 
annealed and cloned into pMIR-REPORT Luciferase reporter vector 
(SpeI and MluI sites, Life Technologies). MCF7 cells were 
cotransfected in 96-well plates with 30ng pMIR-REPORT Luciferase 
reporter vector (Life Technologies), 30 ng pMIR-REPORT beta-
galactosidase reporter control vector (Life Technologies), and either 
with the Allstars negative control siRNA (Qiagen) or miR-10b mimic 
(Qiagen) at 5 nmol/L. Three days later, luciferase activity and beta-
galactosidase activity were quantified using the Luciferase Assay 
System (Promega) and Beta-galactosidase Enzyme Assay System 
(Promega). Luciferase activity was normalized to beta-galactosidase 
activity. 
 
NFκB promoter activity assay 
NF-κB promoter activity was assayed by transfecting U87-2M1 cells 
with the pGL4.32[luc2P/NF-κB-RE/Hygro] vector (Promega) and 
transducing cells with either control decoy vector or miR-10b decoy 
vector. Luciferase activity was normalized to cellular protein levels. 
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Retrieval of survival data from REMBRANDT database  
Survival data from the REMBRANDT database was obtained using an 
advanced analysis method that allowed for the input of 1.5-fold under-
expression or over-expression of genes as a criterion for sieving out 
patients’ gene expression and corresponding survival timepoints. The 
‘all gliomas’ patient cohort was interrogated in all instances. 
 
Statistical analysis 
All data are represented as mean ± standard error of the mean. 
Differences between samples were analyzed using Student’s t-test. 
The statistical analysis of survival data was performed using the log 
rank test followed by Holm-Sidak method for pairwise multiple 
comparison tests. A p value < 0.05 was considered to be statistically 
significant.  
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Chapter 4: Results 
4.1 U87-2M1 is an invasive mesenchymal subline of U87 glioma 
cells 
Orthotopic xenograft mouse models of human glioblastoma multiforme 
(GBM) utilizing existing human GBM cell lines poorly mirror the 
aggressiveness of GBM due to their lack of invasiveness in the mouse 
brain. We adopted the experimental lung metastasis (ELM) assay (143) 
to select for invasive U87 GBM cells. U87 GBM cells were injected into 
the tail vein of nude mice. Resulting lung metastases obtained were 
propagated in vitro and named U87-2M1. U87-2M1 cells grow 
orthotopically in mouse brain with infiltrative finger-like projections, 
unlike U87 tumors which maintain a distinct boundary with the brain 
parenchyma and display little evidence of localized invasion (Figure 7).  
 
 
Figure 7. U87 and U87-2M1 glioma cells were xenografted 
intracranially in Balb c/nude mice for three weeks. Tumor growth was 
visualized by hematoxylin and eosin staining of sectioned brain tissues. 
U87-2M1 tumors are highly infiltrative and vascularized while U87 
tumors are well-circumscribed and comparatively less vascularized. 
Bars equal 200 μm.  
 
U87                                                 U87-2M1 
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To gain a broad overview of the difference in gene expression between 
U87-2M1 and U87 cells, we performed a gene expression profiling on 
the Affymetrix whole human genome platform. Genes that were 
differentially regulated by more than two folds between the two cell 
lines were analyzed using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) (145, 146) to identify gene ontologies 
that were significantly over-represented among the differentially-
regulated genes. In line with our observation of U87-2M1’s 
invasiveness in vivo, gene ontology terms such as ‘cell adhesion’, 
‘vasculature development’ and ‘extracellular structure organisation’ 
came up among the top five most enriched gene ontology terms (Table 
3).  
Gene Ontology Term  Enrichment 
score 
Count % p-value FDR 
GO:0007155 ~  
Cell adhesion 
7.16 72 7.64 5.27E-08 9.52E-05 
GO:0048731 ~  
System development 








3.89 30 3.18 1.11E-08 2.01E-05 
GO:0042060 ~  
Wound healing 
3.46 27 2.86 9.07E-06 1.64E-02 
GO:0048513 ~  
Organ development 
3.32 132 14.0 8.21E-06 1.48E-02 
 
Table 3. Genes that were differentially regulated by more than 2 folds 
between U87-2M1 and U87 cells were screened using DAVID version 
6.7 for enriched biological themes. Six most enriched gene ontology 
terms are listed. FDR, false discovery rate.  
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We hypothesize that the gene ontology terms ‘system development’ 
and ‘organ development’ hint at the presence of a cancer-associated 
reprogramming such as an epithelial-mesenchymal-transition (EMT) 
that could be responsible for the enhanced invasiveness of U87-2M1. 
By western blotting, we noted a clear switch from E-cadherin to N-
cadherin expression as well as increased expression of mesenchymal 
proteins such as vimentin and fibronectin (Figure 8). The observed 
repression of E-cadherin is likely to be mediated by EMT regulator 
TWIST but not SNAI1 or SNAI2 (Figure 8). Enhanced expression of 
STAT3, FOXM1, MMP13, HGF, PLAUR and PLAU (Figure 8), which 
have been previously associated with the mesenchymal (147), cancer 
stem cell (148), invasive and angiogenic (149, 150) phenotypes, clearly 
support U87-2M1 as an invasive GBM line with an acquired 
mesenchymal gene expression. 
 
 
Figure 8. U87-2M1 showed higher endogenous protein expression of 
N-cadherin, fibronectin, vimentin, Twist, Stat3, MMP13, FOXM1, HGF, 
PLAUR and PLAU compared to U87 cells.  
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We asked if miR-10b underlies the enhanced invasiveness of 
U87-2M1 cells and assayed the copy number of miR-10b in U87-2M1, 
five other glioma cell lines as well as normal human astrocytes. 
Consistent with prior evidence that Twist transcribes miR-10b (44), 
miR-10b copy number in U87-2M1 cells is approximately twice higher 
than in U87 cells (Figure 9). U87-2M1 was therefore chosen for further 
studies to elucidate miR-10b’s role in vitro and in vivo.  
 
 
Figure 9. Quantification of miR-10b expression in glioma cell lines 
(SW1088, U87-2M1, U87, T98G, U251 and U138) and normal human 
astrocytes (NHA) revealed an up-regulation of miR-10b expression in 
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To investigate the role of miR-10b in GBM, we designed a 
baculoviral miR-10b decoy vector containing thirteen repeats of a miR-
10b binding site that is highly complementary to miR-10b, as well as a 
control decoy vector with no complementarity to any known human 
microRNA (Figure 10). Thirteen repeats of a binding site were chosen 
as fewer sites resulted in partial interference of miR-10b with no 
significant phenotype observed (data not shown). Given its high 
transduction efficiency in glioma cells (144), we used baculovirus as 
delivery vectors. Although such an approach has been demonstrated to 
interfere with miRNA function successfully (57), baculoviral vectors 






miR-10b UGUCCCAU- GUGUUUAAGCCA 
AGA 
A G 
5’-CACA AATT CGGT      ACAGGGTA  
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Figure 10. Construction of control sponge or miR-10 sponge in 
baculoviral vectors and the transduction efficiency in U87-2M1 cells. A, 
schematic of the expression cassette.  B, sequence of the miR-10b 
binding site and control sequence with no known complementarity to 
any known microRNA. C, baculoviral vectors displays excellent 
transduction efficiency of approximately 94% after two days of 
transducing U87-2M1 cells. 
 
To demonstrate the specificity of our miR-10b decoy vector, 
U87-2M1 cells were transfected with a luciferase vector containing a 
miR-10b binding site in its 3’ untranslated region (UTR) and transduced 
with either the baculoviral miR-10b decoy vector or control decoy 
vector. When the luciferase transgene is co-expressed with a miR-10b 
binding site, our miR-10 decoy vector relieved the suppressive effect of 
endogenous miR-10b on luciferase expression as opposed to the 
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C 
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Figure 11. MicroRNA-10b decoy vector, but not the control decoy 
vector, relieves the suppression of luciferase expression by 
endogenous miR-10b in U87-2M1 glioma cells. Error bars represent 
standard error from three independent experiments; *, p<0.05. 
 
We studied the endogenous expression of miR-10b after 
transduction with miR-10b decoy vector and detected a 75% decrease 
in miR-10b expression, further affirming the specificity of our decoy 
vector in interfering with miR-10b function (Figure 12).  
 
Figure 12. MicroRNA-10b decoy vector decreases the level of 
detectable miR-10b in U87-2M1 glioma cells. Error bars represent 
standard error from three independent transductions; *, p<0.05. 
 
 
 - 66 - 
To demonstrate functional interference of miR-10b in U87-2M1, 
we transduced U87-2M1 cells with our baculoviral control or miR-10b 
decoy vector and performed a gene expression analysis on the 
Affymetrix Genechip Human Genome U133 Plus 2.0 platform. Genes 
that were differentially regulated by more than 1.5 folds after inhibition 
of miR-10b were analyzed using Database for Annotation, Visualization 
and Integrated Discovery (DAVID) (145, 146) to identify gene 
ontologies that were over-represented. Gene ontologies such as 
‘regulation of cell proliferation’, ‘nuclear division’ and ‘regulation of 
programmed cell death’ were significantly over-represented (Table 4), 
supporting prior evidence of a regulatory relationship between miR-10b 
and cell growth (46). Strikingly, gene ontologies representing 
‘regulation of cell motion’ and ‘vasculature development’ were 
significantly enriched as well, suggesting that a complex regulatory 
network exists between miR-10b and genes pertaining to cell growth, 
invasion and angiogenesis.  
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Gene Ontology Term Enrichment 
score 
Count % p-value FDR 
GO:0019222 ~  
Regulation of metabolic 
process 
6.93 401 24.4 1.36E-11 2.53E-08
GO:0042127 ~  
Regulation of cell 
proliferation 
5.26 111 6.74 2.99E-08 5.53E-05
GO:0048522 ~  
Positive regulation of 
cellular process 
5.05 221 13.4 6.95E-09 1.29E-05
GO:0032502 ~  
Developmental process 4.52 333 20.2 3.42E-07 6.34E-04
GO:0000280 ~  
Nuclear division 3.86 39 2.37 1.19E-05 2.21E-02
GO:0051270 ~  
Regulation of cell 
motion 
3.67 35 2.13 2.22E-05 4.10E-02
GO:0001944 ~  
Vasculature 
development 
3.61 43 2.61 9.54E-06 1.77E-02
GO:0043067 ~  
Regulation of 
programmed cell death 
3.56 105 6.38 4.85E-06 8.99E-03
 
 
Table 4. Genes that were differentially regulated by more than 1.5 folds 
after miR-10b silencing in U87-2M1 cells were screened with DAVID 
version 6.7 for identification of biological themes. Eight highest 
enriched gene ontology terms are listed. FDR, false discovery rate. 
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4.2 Inhibition of miR-10b decreases invasiveness of U87-2M1 
glioma cells  
To study miR-10b function in cell invasiveness in vitro, we performed a 
transwell matrigel invasion assay and observed 50% less invaded U87-
2M1 cells after miR-10b inhibition (Figure 13).  
 
 
Figure 13. Inhibition of miR-10b in U87-2M1 cells diminishes its 
capacity to invade through a transwell membrane coated with 
basement membrane matrix. Error bars represent standard error from 
three independent experiments; *, p<0.05. Bars equal 200 μm.  
 
 - 69 - 
U87-2M1 cells transduced with control decoy vector form big, infiltrative 
and highly vascularized tumors in vivo with islands of invading cells 
(Figure 14) while inhibition of miR-10b function in U87-2M1 resulted in 
a profoundly smaller tumor that is with no evidence of localized 
invasion (Figure 14). Quantitative measure of the significance of 
inhibition of miR-10b expression on the invasiveness and growth of 
U87-2M1 in vivo may be done in the future through magnetic 
resonance imaging on the distribution and quantity of intracranial U87-
2M1 lesions. 
 
Figure 14. Prior silencing of miR-10b in U87-2M1 cells in vitro reduces 
growth of orthotopic tumor with no evident signs of localized invasion. 
U87-2M1 cells transduced with control decoy vector displayed 
aggressive growth, high vascularization and localized invasion. 
Invading cells are indicated by arrows. Bars equal 50 μm.  
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To understand the molecular mechanism underlying the regulation of 
invasion by miR-10b, we performed western blotting and observed a 
clear increase in HOXD10 protein level and a reduction in RhoC and 
PLAUR protein expression (Figure 15). Our observation is consistent 
with prior reports on miR-10b as a negative regulator of HOXD10 in 
metastatic breast cancer (44) and glioblastoma multiforme (47). We 
questioned if the repression of other invasive proteins contributed to 
the decrease in U87-2M1 cell invasion after miR-10b inhibition and 
found PLAU, CTNNB, HGF and MMP13 to be significantly down-
regulated (Figure 15). Our results point to a broad suppression of 
invasive proteins after miR-10b inhibition, most likely through indirect 
mechanisms.  
 
Figure 15. MicroRNA-10b silencing reduces protein expression of β-
catenin, MMP13, RhoC, PLAUR, PLAU and HGF and upregulates 
HOXD10 protein expression. 
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To rule out any possibility that the vast decrease in invading U87-2M1 
cells was entirely attributed to apoptotic cell death after miR-10b 
inhibition, we transfected miR-10b mimics into U87-2M1 cells and 
observed an over 2-fold increase in invaded cells (Figure 16A) with no 
accompanying increase in cell proliferation or viability (Figure 16B). By 
excluding cell death as a confounding variable in our cell invasion 




Figure 16. Over-expression of miR-10b promotes invasiveness of U87-
2M1. Transfection of exogenous miR-10b in U87-2M1 augments its 
invasion in a transwell invasion assay by over 2 folds. Error bars 
represent standard error from three independent experiments. Bars 
equal 200 μm. 
B 
A 
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4.3 miR-10b silencing decreases angiogenicity of U87-2M1 glioma 
cells  
Given the intricate links between cell invasion and angiogenesis, we 
investigated the angiogenicity of U87-2M1 tumor after miR-10b 
inhibition by performing immunohistochemical staining for CD31, an 
endothelial cell marker. U87-2M1 cells pre-transduced with control 
decoy vector showed an enrichment of CD31 cells as well as a 
migratory tract of CD31-positive cells with numerous CD31-positive 
vessels (Figure 17). Remarkably, U87-2M1 cells transduced with miR-
10b decoy vector form a much smaller tumor that is only weakly 
positive for CD31 (Figure 17).  
 
Figure 17. Inhibition of miR-10b suppresses angiogenesis by U87-2M1 
glioma cells. Intracranial tumors produced from miR-10b or control 
decoy vector-transduced U87-2M1 cells were sectioned and 
immunostained using antibody against CD31. Bars equal 200 μm.  
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Culture supernatant from miR-10b decoy vector-transduced U87-2M1 
is significantly less potent than that from control decoy vector-
transduced U87-2M1 in inducing tubule formation from human vascular 
endothelial cells, further supporting the decreased angiogenic protein 
production in U87-2M1 cells (Figure 18). 
 
Figure 18. Angiogenic potential of U87-2M1 cells were determined by 
an in vitro endothelial cell tube formation assay. Conditioned medium 
from U87-2M1 cells transduced with control or miR-10b decoy vector 
were added to human vascular endothelial cells plated on Matrigel. 
Bars equal 200 μm.  
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To appreciate the molecular mechanisms underlying the decreased 
angiogenicity in U87-2M1, we performed western blotting and found a 
pervasive decrease in expression of angiogenic proteins such as 
VEGF, IL8 and TGFB2 (Figure 19). This evidence further supports our 
finding that U87-2M1 is an invasive and angiogenic subline of U87 
glioma cells.  
 
Figure 19. MicroRNA-10b likely reduces angiogenic potential of U87-
2M1 by decreasing expression of pro-angiogenic proteins such as 
VEGF, IL8, TGFβ2, CTGF and THBS1.  
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We examined the group of angiogenic factors which the DAVID 
analysis (Table 4) picked up. In particular, all thirteen angiogenic 
proteins down-regulated by miR-10b inhibition were found to be widely 
expressed in the Mesenchymal subtype of glioblastoma multiforme 
(GBM) in the dataset from The Cancer Genome Atlas as defined by 
Verhaak et al (137) (Figure 20). This panel of thirteen proteins is, to a 
lesser extent, expressed in the Classical subtype of GBMs and under-
expressed or not as differentially regulated in the Neural and Proneural 
subtypes of GBMs (Figure 20). This finding suggests that the 
Mesenchymal subtype of GBMs has a distinct pro-angiogenic signature 
which may be co-regulated by miR-10b. 
 
Figure 20. A panel of 13 angiogenic genes down-regulated by miR-10b 
silencing is frequently over-expressed in the Mesenchymal subgroup of 
glioblastoma multiforme (GBM). Most of the genes in this panel are 
less frequently over-expressed in the Classical subgroup of GBM, and 
frequently under-expressed in the ‘Neural’ and ‘Proneural’ subgroups 
of GBM. 
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4.4 Inhibition of miR-10b expression increases apoptosis of U87-
2M1 glioma cells and prolongs survival of U87-2M1-bearing mice 
We questioned if miR-10b’s cellular effects on promoting invasion and 
suppressing apoptosis was necessarily mutually exclusive (46). Having 
demonstrated a profound effect of miR-10b on glioma invasion in vitro 
and in vivo, we performed cell cycle analysis on propidium iodide-
stained U87-2M1 cells with or without miR-10b inhibition. miR-10b 
silencing in U87-2M1 causes the G0 or SubG1 population to increase 
by 13% (Figure 21).  
 
 
Figure 21. MicroRNA-10b silencing promotes apoptosis of U87-2M1 
cells. Propidium iodide staining shows increased number of propidium 
iodide-positive cells after miR-10b silencing.  
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Moreover, MTS viability assay showed an approximate 40% decrease 
in cell viability after miR-10b inhibition (Figure 22).  
 
Figure 22. MTS assay shows a decrease in cell viability after inhibition 
of miR-10b. Error bars represent standard error from three independent 
experiments; *, p<0.05. 
 
Further evidence of enhanced caspase activity after miR-10b inhibition 
came from the higher luminescence detected after cleavage of the 
caspase-sensitive Casp-Glo 3/7 substrate (Figure 23). 
 
Figure 23. Elevated caspase activity after miR-10b silencing was 
detected by the use of a caspase-sensitive Casp-Glo reagent. Error 
bars represent standard error from three independent experiments; *, 
p<0.05.  
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Western blotting further confirmed elevated caspase activation with a 
distinct increase in cleaved caspase 3, cleaved caspase 7 and pro-
apoptotic Bim protein levels after miR-10b inhibition (Figure 24).  
 
Figure 24. Western blotting confirms increased protein expression of 
cleaved caspase-3 and cleaved caspase-7, demonstrating that 
silencing of miR-10b promotes caspase cleavage and apoptosis. 
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To provide evidence of miR-10b’s anti-apoptotic role in vivo, we 
inoculated nude mice subcutaneously with U87-2M1 cells to establish 
tumors. This approach allowed us to precisely verify that our 
baculoviral vectors were injected into tumor due to the lack of imaging 
techniques that allow us to visualize and verify the specific 
administration of baculoviral vectors in intracranial tumors. Baculoviral 
vector harboring either the control decoy or miR-10b decoy was 
injected into a U87-2M1 subcutaneous tumor. TUNEL staining on U87-
2M1 tumor sections showed that miR-10b decoy vector was able to 
extensively induce apoptosis in the tumor whereas the control decoy 
vector showed limited apoptosis at the tumor injection site (Figure 25).  
 
Figure 25. Delivery of miR-10b decoy vector, but not the control decoy 
vector, into a subcutaneous U87-2M1 tumor results in enhanced 
TUNEL-positive staining. Bars equal 100 μm. 
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Mice intracranially implanted with U87-2M1 cells pretreated with miR-
10b decoy vector survived approximately six days longer than those 
with control decoy vector or PBS, demonstrating a survival benefit in 
knocking down miR-10b in U87-2M1 glioma-bearing mice (Figure 26).  
 
 
Figure 26. Mice bearing U87-2M1 tumors that arose from prior 
treatment in vitro with PBS, control decoy vector, or miR-10b decoy 
vector showed significantly different survival trends. Ten mice were 
used for each treatment group. PBS versus Control decoy vector, 
p>0.06; PBS versus miR-10b decoy vector, p<0.03; Control decoy 
vector versus miR-10b decoy vector, p<0.0007. 
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4.5 Pleiotropic miR-10b regulates a broad range of tumor 
suppressors 
To identify the mRNA targets of miR-10b in U87-2M1, we screened 
through the list of differentially regulated genes to identify potential 
tumor suppressor proteins that were up-regulated after miR-10b 
inhibition. The entire sequence of the longest mRNA transcript variant 
for every tumor suppressor gene of interest was scrutinized using 
rna22 (6) to identify miR-10b binding sites. Based on our earlier finding 
that β-catenin is degraded after miR-10b inhibition, we identified the 
familial cylindromatosis tumor suppressor gene, CYLD, as one such 
negative regulator of the Wnt/β-catenin pathway (151). CYLD is also a 
known negative regulator of NFкB signaling, itself a transcriptional 
activator of IL8 (152). The entire CYLD transcript contains two 
predicted miR-10b binding sites – CYLD 1854 (from nucleotide position 
1854-1876 residing in the coding sequence) and CYLD 5302 (position 
5302-5324 residing in the 3’ untranslated region) (Figure 27). Likewise, 
two predicted miR-10b sites were identified in tumor suppressors TP53 
(TP53 2564 and TP53 2313), two in Notch1 (Notch1 7920 and Notch1 
1307), five in Ptch1 (Ptch1 5446, Ptch1 7023, Ptch1 279, Ptch1 1302 
and Ptch1 4175) two in Pax6 (Pax6 2969 and Pax6 2364) and two in 
FOXO3A (FOXO3A 2592 and FOXO3A 688) (Figure 27). Although 
TP53 was not shown to be a significantly differentially regulated gene 
from microarray analysis, we noted an increased expression of MDM2, 
GADD45A and GADD45B which are downstream effectors of TP53, 
suggesting a possible over-expression of TP53 at the protein level.  
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Figure 27. Predicted miR-10b binding sites in TP53, FOXO3, PAX6, 
CYLD, PTCH1 and NOTCH1. RNA22-predicted miR-10b binding sites 
and their corresponding predicted folding energies are shown.  
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We performed luciferase reporter assays to verify the efficacy of the 
predicted binding sites. HOXD10 was included as a positive control. 
Luciferase reporter assays showed that miR-10b repressed all fifteen 
putative miR-10b binding sites (Fig. 28). MicroRNA recognition of 
target mRNAs relies primarily on the pairing of the miRNA seed 
sequence to the target site. We mutated the putative miR-10b binding 
sites in the region important for pairing with miR-10b’s seed sequence 
and observed amelioration of miR-10b-mediated luciferase repression 
in seven mutated binding sites (Fig. 28). 
   
 
Figure 28. Identification of TP53, FOXO3, CYLD, NOTCH1, PTCH1 
and PAX6 as targets of miR-10b. Response of luciferase reporters 
harboring either the predicted miRNA target site or its corresponding 
mutant form, after co-delivery of miR-10b or control siRNA into MCF7 
cells are shown. Error bars represent standard error from three to four 
independent transfections.  
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Endogenous CYLD, TP53, FOXO3A, PAX6, NOTCH1 and PTCH1 
protein levels were assayed in U87-2M1 cells after silencing of miR-
10b. In support of these results, inhibition of miR-10b enhanced the 
endogenous protein expression of all six predicted targets in U87-2M1 
cells (Figure 29). These data indicate that miR-10b directly regulates 
endogenous CYLD, TP53, FOXO3A, PAX6, NOTCH1 and PTCH1.  
 
 
Figure 29. Silencing of miR-10b up-regulates target proteins TP53, 
FOXO3, CYLD, PTCH1, NOTCH1 and PAX6. 
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CYLD has a dampening effect of NFkB pathway activation which 
in itself exerts angiogenic properties and protects against apoptosis 
among its many roles (153). CYLD’s deubiquitination of NFкB inhibits 
NFкB activity in a manner that does not rely on decreased NFкB 
protein expression (154, 155). In agreement with that finding, we 
observed a decrease in NFкB transcriptional activity (Figure 30) even in 
the absence of a clear down-regulation of NFкB-p65 expression 
(Figure 29) and consequently, decreased expression of IL8 and VEGF 
(Figure 19).  
 
Figure 30. NFkB transcriptional activity is significantly lower in miR-
10b-silenced U87-2M1 cells. Error bars represent standard error from 
three independent experiments; *, p<0.05. 
 
Increased CYLD expression may likewise diminish Wnt pathway 
activation and β-catenin accumulation (Figure 15) via K63-linked 
deubiquitination of Dvl (151). Decreased expression of β-catenin could 
also be a consequence of enhanced Notch1 expression (Figure 29) 
which has a demonstrated tumor suppressive function in mouse skin 
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(156). In addition, the sonic hedgehog (Shh) and Wnt pathways 
collaborate to regulate cell cycle progression via the production of early 
and late cyclins in neural progenitor cells (157). Therefore, increased 
expression of Ptch1 (Figure 29) could exert a suppressive effect on the 
Shh pathway and act synergistically with loss of β-catenin expression 
to halt cell cycle progression. β-catenin’s oncogenic role may be further 
augmented by the expression of FOXM1 in glioblastoma (158). FOXM1 
is overexpressed in glioblastomas (159), transcribes VEGF (149) and 
critically mediates β-catenin’s nuclear translocation in the absence of 
conventional Wnt pathway activation (158). Others have shown that 
FOXM1 may be negatively regulated by TP53 (160, 161) and FOXO3 
(162). In agreement with those findings, we observed a down-
regulation of FOXM1 protein expression together with up-regulation of 
TP53 and FOXO3 expression (Figure 29) after inhibition of miR-10b. 
Up-regulation of FOXO3 is known to activate pro-apoptotic Bim which 
is itself a target of miR-10b (46). In addition, up-regulation of FOXO3 
provides an alternative mechanistic explanation for the down-regulation 
of NFкB activity (163) that we observed after miR-10b silencing. Other 
than a possible role for TP53 in repression of FOXM1, TP53’s 
activation may activate p21 expression (164) and inhibit expression of 
fibronectin (165) and thrombospondin1 (166) which were observed 
after silencing of miR-10b (Figure 29). Furthermore, TP53 is 
phosphorylated at Ser15 and Ser20, thus diminishing the ability of 
Mdm2 in negating TP53 activity (Figure 29). Up-regulation of PAX6 
after miR-10b silencing (Figure 29) may result in decreased 
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angiogenicity and invasiveness partly due to PAX6’s suppression of 
VEGFA  (167) and MMP2 (168).  
Our findings point to a complex regulatory framework centered 
on miR-10b (Figure 31). Via the coordinate suppression of multiple 
tumor suppressors, miR-10b suppresses the expression of cell cycle 
inhibitors and promotes expression of invasive proteins and angiogenic 
molecules.  
 
Figure 31. A mechanistic model summarizing the pleiotropic actions of 
miR-10b. 
 
4.6 Perturbation of direct and indirect targets of miR-10b 
correlates with poorer patient survival 
To assess the importance of the various tumor suppressors 
regulated by miR-10b, we assessed the relevant patient survival rates 
by interrogating the REMBRANDT database (169). At a fold-change 
threshold of 1.5, we noted PAX6, CYLD, FOXO3, Ptch1 and Notch1 to 
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be associated with significantly lower patient survival (Figure 32). A 
lack of association between diminished p21, TP53, Bim, HOXD10 and 
patient survival (Figure 32) may be attributed to the prevalence of 
mutational inactivation in tumor suppressors that do not necessarily 
compromised their mRNA expression (45).  
 
Figure 32. Perturbed expression of direct targets of miR-10b are 
associated with poor patient survival. Red line denotes survival curve 
of patients with more than 1.5 fold underexpression of the gene of 
interest. Blue line denotes survival curve of patients with less than 1.5 
fold underexpression of the gene of interest.  
 
More conclusively, all oncogenic proteins that were indirect 
targets of miR-10b are significantly associated with poorer patient 
survival at fold-change threshold of 1.5 (Figure 33). 
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Figure 33. Upregulation of indirect oncogenic targets of miR-10b 
significantly correlates with poor patient survival. Red line denotes 
survival curve of patients with more than 1.5 fold overexpression of the 
gene of interest. Blue line denotes survival curve of patients with less 
than 1.5 fold overexpression of the gene of interest.  
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Chapter 5: Discussion 
A lack of preclinical models that accurately portray human 
glioblastoma multiforme (GBM) precludes a clear investigation of 
glioma biology. In the present report, subjecting U87 glioma cell line to 
an experimental lung metastasis assay (143) allowed the derivation of 
a mesenchymal and invasive subline of U87 cells which we termed 
U87-2M1. Enhanced malignancy of U87-2M1 as opposed to parental 
U87 cells could be in part due to an increased expression of miR-10b. 
Baculoviral vector encoding a miR-10b sponge was found to sufficiently 
silence miR-10b activity, resulting in the detection of broad changes to 
U87-2M1’s cell growth, motility and angiogenicity on a microarray 
platform. The pleiotropic manner of miR-10b’s action in this study stood 
in direct contrast to earlier reports of miR-10b’s exclusive regulation of 
either glioma cell growth and death (46), or glioma invasion (47). 
Although miR-10b’s impact on cell cycle and apoptosis may appear to 
confound our findings on miR-10b’s regulation of glioma invasion, miR-
10b gain-of-function studies showed that miR-10b is able to positively 
regulate cell invasion. In addition, other invasive proteins such as 
MMP13, MMP2, β-catenin and HGF are down-regulated after miR-10b 
silencing, supporting a role for miR-10b’s regulation of glioma invasion. 
Various groups have undertaken efforts using unsupervised 
hierarchical clustering to delineate pathways or gene expression 
signatures that are preferentially activated in each subtype of 
glioblastoma multiforme (GBM) (137, 170), suggesting that the 
biological behaviour and malignancy of each GBM subtype is likely to 
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be different even though all glioblastoma specimens investigated by 
TCGA were uniformly GBM. We noted that the lack of correlation 
between miR-10b and glioma invasion was made in the context of the 
more than 200 glioblastoma cases under the TCGA study (46), where 
only less than 30% of all glioblastoma cases were categorized as 
having a Mesenchymal signature (137, 171). Although miR-10b may 
universally regulate glioma cell growth and death regardless of the 
GBM subtype being studied, it seems plausible that additional roles for 
miR-10b may arise depending on the mRNA expression in any cellular 
context. In our study, we have shown that HOXD10, PAX6, CYLD and 
Notch1 may coordinately regulate invasive factors such as RhoC, 
PLAUR, MMP2 and β-catenin. Other than governing invasiveness of 
U87-2M1 glioma cells, we have also demonstrated that miR-10b 
displays the same propensity towards regulation of U87-2M1 cell death 
and growth. This challenges the notion that miR-10b exclusively 
performs a singular role of either promoting cell invasion (44), or cell 
growth (46). Of particular interest, Ma et al (44) observed a significant 
increase in the weight of SUM149 mammary tumors stably expressing 
miR-10b as opposed to control tumors from the ninth week of SUM149 
xenograft development. Although the authors suggested that the 
invasiveness of the cells gave rise to better access to vasculature that 
aid tumor development, we reckon the development of tumors in vivo 
provided microenvironmental signals, for example hypoxia, which may 
modulate the repertoire of mRNA expression and allow miR-10b to 
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simultaneously promote cancer cell growth and invasion whilst 
suppressing apoptosis. 
We have also demonstrated a previously unappreciated role for 
miR-10b in regulating glioma angiogenesis. This is not improbable 
since many proteins act pleiotropically in suppressing tumor 
progression. Furthermore, Ma et al (44) reported the finding of highly 
proliferative and angiogenic SUM149 mammary cancer cells at the 
invasive fronts of an in vivo SUM149 tumor stably expressing miR-10b, 
suggesting that it is indeed possible for miR-10b to act in a pleiotropic 
manner that was previously unknown . Microarray analyses revealed a 
panel of thirteen angiogenic molecules that was down-regulated after 
miR-10b silencing. (169). Out of these thirteen proteins, twelve of them 
have been implicated in glioma malignancy and angiogenesis. 
ANGPT1 (172), ANXA2 (173), COL1A2 (46, 47), CTGF (48, 49), 
ITGA4 (174), JAG1 (174), LAMA4 (174), LOX (49), THBS1 (174), 
TGFA (49-51) and TGFB2 (174) have been demonstrated to positively 
regulate the angiogenic, invasive or mesenchymal gene expression in 
glioma cells while LEPR has also been shown to be a key receptor for 
leptin-mediated angiogenesis in acute myeloid leukemia (175). RECK, 
on the other hand, has been extensively characterized as an anti-
angiogenic molecule via its inhibition of matrix metalloproteinase 
activity and its expression in a mesenchymal glioma cell seems 
paradoxical. However, RECK has also been shown to have an MMP-
independent function. Osteoarthritic chondrocytes proliferating in 
response to mitogens such as TGF-β required the presence of RECK 
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and the silencing of RECK reduced the proliferation of TGF-β-
stimulated chondrocytes (43). This finding suggests that RECK and 
TGF-β coordinately and positively regulates cell proliferation in an 
inflammatory setting. Since the Mesenchymal subgroup of GBM is 
characterized by a high expression of genes from the NF-κB pathway, 
RECK likely plays a pro-proliferative, rather than anti-angiogenic, role 
in mesenchymal U87-2M1 cells. Moreover, RECK over-expression is 
associated with poor patient survival rate in the REMBRANDT dataset 
(p=0.002), suggesting that RECK is an oncogene in gliomagenesis 
(Figure 33). Similarly, THBS1 has been widely regarded as a tumor 
suppressor via its inhibition of angiogenesis (176). However, patient 
survival data from the REMBRANDT database reveals a highly 
significant link between THBS1 over-expression and poor survival rates 
(Figure 33) (169). We speculate that THBS1 acts as an oncogene via 
activatation of latent TGF-β in the extracellular environment (177). We 
observed that down-regulation of pro-angiogenic Notch ligand, 
Jagged1, enables Notch1 receptor to act as a tumor suppressor via its 
sequestration of β-catenin, hence avoiding conflict with its potential 
angiogenic contribution via Jagged1 activation. Our results collectively 
indicate a reduced angiogenicity of U87-2M1 glioma cells mediated by 
inhibition of miR-10b. 
 Our findings further confirmed the utility of miR-10b silencing for 
glioma therapy. Even though miR-10b has been established to regulate 
cell cycle progression and apoptosis across all gliomas, miR-10b’s 
oncogenic role should be expanded to include regulation of 
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angiogenesis and invasion, at least, in the Mesenchymal subtype of 
gliomas.  
 
Chapter 6: Conclusion and future studies 
 
 
This work aims to understand the contribution of miR-10b to GBM 
etiology. To this end, we demonstrated that baculoviral vectors can 
antagonize endogenous miR-10b function by the expression of decoy 
miR-10b binding sites. Derepression of miR-10b’s mRNA targets in 
invasive U87-2M1 cells resulted in a broad spectrum of anti-tumor 
effects such as increased cell death, suppressed invasion and 
angiogenicity. Our results stand in contrast to current findings that miR-
10b exclusively regulates GBM growth or invasion but not both 
concurrently. Our study shows that in an invasive subline of U87 
glioma cells exhibiting mesenchymal properties, miR-10b may behave 
as a pleiotropic regulator of gliomagenesis by suppressing glioma cell 
death while promoting glioma cell invasion, growth and angiogenesis. 
Our data is however circumstantial and limited to our derived U87-2M1 
cell line and more work needs to be done in multiple lines that 
resemble the mesenchymal subtype of GBM if possible. 
Although miR-10b regulation of glioma growth, invasion and 
angiogenesis may be explained by its suppression of multiple tumor 
suppressors, is not immediately apparent why prior studies on miR-10b 
in GBM did not manage to delineate the intricate co-regulatory 
relationship between miR-10b and glioma growth, angiogenicity and 
invasion. A possible reason could be the adaptation of the commonly 
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used glioma cell lines to in vitro culture, thus the transcriptome of such 
cells are biased towards the promotion of cell growth in vitro. Since a 
miRNA’s ability to target genes is dependent on the cellular 
transcriptome, the true role of miR-10b can only be investigated using 
glioma cells that resemble, as much as possible, human pathological 
GBM. The derivation of an invasive and mesenchymal subline of U87 
glioma cells precisely allowed us to monitor the effects of silencing 
miR-10b in GBM cells resembling the Mesenchymal subtype of GBM. It 
will be of interest to understand the effects of miR-10b on other glioma 
cell lines displaying a mesenchymal gene expression. Whether miR-
10b possesses such a pleiotropic role in other subgroups of glioma 
requires further investigation via the development of in vitro models 
which accurately mimic the other GBM subgroups. 
 It is tempting to speculate that, since expression of miR-10b is 
extremely low in brain, delivery of miR-10b sponge into healthy cells 
located in the vicinity of the tumor should not presumably be 
detrimental to healthy cells; making miR-10b becomes an attractive 
therapeutic target. Any toxicity that may arise in such a cancer gene 
therapy approach should be associated only with the viral vector used. 
Future studies may include the investigation of the growth of U87-2M1 
glioma xenografts after receiving intracranial injections of baculoviral 
vectors expressing the miR-10b sponge. This evidence will support a 
possible clinical application of delivery of miR-10b sponge by 
baculoviral vectors for glioma gene therapy. Further evidence of safety 
may arise from comparing the toxicity issues arising from intracranial 
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administration of baculoviral vectors expressing miR-10b sponge or 
anti-miR-10b oligonucleotides which is currently perceived to be the 
gold standard for miRNA-knockdown therapy. Further assessments of 
safety may be done through in vitro administration of baculoviral 
vectors expressing miR-10b sponge to primary or embryonic stem cell-
derived human cells with an origin in the brain, such as neural 
progenitor cells, neurons, astrocytes, oligodendrocytes, microglia and 
brain microvascular endothelial cells. This should provide further clarity 
on the safety of a therapeutic approach centered on miR-10b targeting. 
Further avenue of research may be centred on identification of novel 
miR-10b targets and one such approach may be the identification of 
genes that have lower expression in U87-2M1 versus U87 cells and 
whose expression in U87-2M1 cells increase after inhibition of miR-10b 
function. We have identified a novel candidate gene BCL11B whose 
lowered expression in the REMBRANDT database is associated with 
poorer patient survival (data not shown). The identification of novel 
miR-10b target genes using such a strategy may provide further clues 
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